 Akers Biosciences, Inc. the Company AKER, a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Companys common stock, at a purchase price of 3.53 per share, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately 4.8 million, before deducting the placement agents fees and other offering expenses payable by the Company. 